Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

Yesafili is a VEGF inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), ...

4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.

Updated results from the second year of the KITE study found that intraocular inflammation (IOI) was seen in 2.2% of Beovu patients, compared to 1.7% of the Eylea group, with no cases of RV with ...

An estimated 50 million people live with the irritating symptoms of dry eye, including redness, blurry vision, and a scratchy ...